A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
- Resource Type
- Article
- Source
- Blood Advances; January 2024, Vol. 8 Issue: 2 p429-440, 12p
- Subject
- Language
- ISSN
- 24739529; 24739537